The role of PET/CT in the management of cervical cancer

American Journal of Roentgenology

Volumn 201, Issue 2, 2013, Pages

  Mirpour, Sahar ^a   Mhlanga, Joyce C ^a   Logeswaran, Prashanti ^b   Russo, Gregory ^b   Mercier, Gustavo ^b   Subramaniam, Rathan M ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cervical cancer; Hypoxia; Outcome; PET CT

Indexed keywords

DIACETYLBIS(N4 METHYLTHIOSEMICARBAZONE) CU 60; FLUORODEOXYGLUCOSE F 18; IODIXANOL; IOHEXOL; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

BRACHYTHERAPY; CANCER CLASSIFICATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DECISION MAKING; DIAGNOSTIC VALUE; EXTERNAL BEAM RADIOTHERAPY; HUMAN; LONG TERM SURVIVAL; MULTIDETECTOR COMPUTED TOMOGRAPHY; PET SCANNER; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE; UNITED STATES; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA; WHOLE BODY IMAGING;

FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 84883665330     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.9830     Document Type: Review

References (91)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108
2. Howlader N, Noone AM, Krapcho M, et al., eds. SEER Cancer Statistics Review, 1975-2008. National Cancer Institute website. seer.cancer.gov/csr/1975- 2008. Based on November 2010 SEER data submission. Posted 2011. Accessed March 26, 2013
3. Arbyn M, Castellsagué X, de Sanjosé S, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011; 22:2675-2686
4. Stanley M. Human papillomavirus vaccines versus cervical cancer screening. Clin Oncol (R Coll Radiol) 2008; 20:388-394
5. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96
6. Plummer M, Franceschi S. Strategies for HPV prevention. Virus Res 2002; 89:285-293
7. Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging 2008; 8:146-155
8. Son H, Kositwattanarerk A, Hayes MP, et al. PET/CT evaluation of cervical cancer: Spectrum of disease. RadioGraphics 2010; 30:1251-1268
9. Chaturvedi AK, Kleinerman RA, Hildesheim A, et al. Second cancers after squamous cell carcinoma and adenocarcinoma of the cervix. J Clin Oncol 2009; 27:967-973
10. Schorge JO, Knowles LM, Lea JS. Adenocarcinoma of the cervix. Curr Treat Options Oncol 2004; 5:119-127
11. Imadome K, Iwakawa M, Nakawatari M, et al. Subtypes of cervical adenosquamous carcinomas classified by EpCAM expression related to radiosensitivity. Cancer Biol Ther 2010; 10:1019-1026
12. Waggoner SE. Cervical cancer. Lancet 2003; 361:2217-2225
13. Kumar VA, Fausto N, Mitchell RN. Robbins basic pathology. Philadelphia, PA: Saunders Elsevier, 2007:718-721
14. Canavan TP, Doshi NR. Cervical cancer. Am Fam Physician 2000; 61:1369-1376
15. James RM, Cruickshank ME, Siddiqui N. Management of cervical cancer: Summary of SIGN guidelines. BMJ 2008; 336:41-43
16. Kanthan R, Senger JL, Diudea D, Kanthan S. A review of duodenal metastases from squamous cell carcinoma of the cervix presenting as an upper gastrointestinal bleed. World J Surg Oncol 2011; 9:113
17. Kindermann G, Jabusch HP. The spread of squamous cell carcinoma of the uterine cervix into the blood-vessels. Arch Gynakol 1972; 212:1-8
18. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009; 105:103-104
19. Hricak H, Gatsonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: Results of the Intergroup Study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 2005; 23:9329-9337
20. Yang WT, Lam WW, Yu MY, Cheung TH, Metreweli C. Comparison of dynamic helical CT and dynamic MR imaging in the evaluation of pelvic lymph nodes in cervical carcinoma. AJR 2000; 175:759-766
21. Subak LL, Hricak H, Powell CB, Azizi L, Stern JL. Cervical carcinoma: Computed tomography and magnetic resonance imaging for preoperative staging. Obstet Gynecol 1995; 86:43-50
22. Hricak H, Lacey CG, Sandles LG, Chang YC, Winkler ML, Stern JL. Invasive cervical carcinoma: Comparison of MR imaging and surgical findings. Radiology 1988; 166:623-631
23. Sheu MH, Chang CY, Wang JH, Yen MS. Preoperative staging of cervical carcinoma with MR imaging: A reappraisal of diagnostic accuracy and pitfalls. Eur Radiol 2001; 11:1828-1833
24. Kim SH, Choi BI, Han JK, et al. Preoperativestaging of uterine cervical carcinoma: Comparison of CT and MRI in 99 patients. J Comput Assist Tomogr 1993; 17:633-640
25. Chung HH, Kang SB, Cho JY, et al. Can preoperative MRI accurately evaluate nodal and parametrial invasion in early stage cervical cancer? Jpn J Clin Oncol 2007; 37:370-375
26. Follen M, Levenback CF, Iyer RB, et al. Imaging in cervical cancer. Cancer 2003; 98:2028-2038
27. Bipat S, Glas AS, van der Velden J, Zwinderman AH, Bossuyt PM, Stoker J. Computed tomography and magnetic resonance imaging in staging of uterine cervical carcinoma: A systematic review. Gynecol Oncol 2003; 91:59-66
28. Hricak H. Role of imaging in the evaluation of pelvic cancer. Important Adv Oncol 1991; 103-133
29. Fischerova D, Cibula D, Stenhova H, et al. Transrectal ultrasound and magnetic resonance imaging in staging of early cervical cancer. Int J Gynecol Cancer 2008; 18:766-772
30. Innocenti P, Pulli F, Savino L, et al. Staging of cervical cancer: Reliability of transrectal US. Radiology 1992; 185:201-205
31. Sun LT, Ning CP, Liu YJ, et al. Is transvaginal elastography useful in pre-operative diagnosis of cervical cancer? Eur J Radiol 2012; 81:e888-e892
32. Thomas A, Kummel S, Gemeinhardt O, Fischer T. Real-time sonoelastography of the cervix: Tissue elasticity of the normal and abnormal cervix. Acad Radiol 2007; 14:193-200
33. Davison JM, Ozonoff A, Imsande HM, Grillone GA, Subramaniam RM. Squamous cell carcinoma of the palatine tonsils: FDG standardized uptake value ratio as a biomarker to differentiate tonsillar carcinoma from physiologic uptake. Radiology 2010; 255:578-585
34. Karantanis D, O'Neill BP, Subramaniam RM, et al. Contribution of F-18 FDG PET-CT in the detection of systemic spread of primary central nervous system lymphoma. Clin Nucl Med 2007; 32:271-274
35. Dibble EH, Alvarez AC, Truong MT, Mercier G, Cook EF, Subramaniam RM. 18F-FDG metabolic tumor volume and total glycolytic activity of oral cavity and oropharyngeal squamous cell cancer: Adding value to clinical staging. J Nucl Med 2012; 53:709-715
36. Jackson T, Chung MK, Mercier G, Ozonoff A, Subramaniam RM. FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site. Nucl Med Commun 2012; 33:305-312
37. Romesser PB, Qureshi MM, Shah BA, et al. Superior prognostic utility of gross and metabolic tumor volume compared to standardized uptake value using PET/CT in head and neck squamous cell carcinoma patients treated with intensity-modulated radiotherapy. Ann Nucl Med 2012; 26:527-534
38. Subramaniam RM, Wilcox B, Aubry MC, Jett J,Peller PJ. 18F-fluoro-2-deoxy-D-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol 2009; 53:160-169
39. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors. Part 2. AJR 2011; 197:[web]W260-W265
40. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases. Part 1. AJR 2011; 197:[web]W256-W259
41. Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR 2011; 197:284-294
42. Park W, Park YJ, Huh SJ, et al. The usefulness of MRI and PET imaging for the detection of parametrial involvement and lymph node metastasis in patients with cervical cancer. Jpn J Clin Oncol 2005; 35:260-264
43. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004; 45(SUPPL. 1):56S-65S
44. Lin LL, Yang Z, Mutic S, Miller TR, Grigsby PW. FDG-PET imaging for the assessment of physiologic volume response during radiotherapy in cervix cancer. Int J Radiat Oncol Biol Phys 2006; 65:177-181
45. Lee YY, Choi CH, Kim CJ, et al. The prognostic significance of the SUVmax (maximum standardized uptake value for F-18 fluorodeoxyglucose) of the cervical tumor in PET imaging for early cervical cancer: Preliminary Results. Gynecol Oncol 2009; 115:65-68
46. Ma DJ, Zhu JM, Grigsby PW. Tumor volume discrepancies between FDG-PET and MRI for cervical cancer. Radiother Oncol 2011; 98:139-142
47. Kaur H, Loyer EM, Minami M, Charnsangavej C. Patterns of uterine enhancement with helical CT. Eur J Radiol 1998; 28:250-255
48. Vick CW, Walsh JW, Wheelock JB, Brewer WH. CT of the normal and abnormal parametria in cervical cancer. AJR 1984; 143:597-603
49. Grigsby PW. The contribution of new imaging techniques in staging cervical cancer. Gynecol Oncol 2007; 107:S10-S12
50. Kidd EA, Spencer CR, Huettner PC, et al. Cervical cancer histology and tumor differentiation affect 18F-fluorodeoxyglucose uptake. Cancer 2009; 115:3548-3554
51. Chou HH et al. Low value of [18F]-fluoro-2-deoxy- d-glucose PET in primary staging of earlystage cervical cancer before radical hysterectomy. J Clin Oncol 2006; 24:123-128
52. Gouy S, Morice P, Narducci F, et al. Nodal-staging surgery for locally advanced cervical cancer in theera of PET. Lancet Oncol 2012; 13:e212-e220
53. Pandharipande PV, Choy G, del Carmen MG, Gazelle GS, Russell AH, Lee SI. MRI and PET/CT for triaging stage IB clinically operable cervical cancer to appropriate therapy: Cecision analysis to assess patient outcomes. AJR 2009; 192:802-814
54. Sala E, Wakely S, Senior E, Lomas D. MRI of malignant neoplasms of the uterine corpus and cervix. AJR 2007; 188:1577-1587
55. Mitchell DG, Snyder B, Coakley F, et al. Early invasive cervical cancer: Tumor delineation by magnetic resonance imaging, computed tomography, and clinical examination, verified by pathologic results, in the ACRIN 6651/GOG 183 intergroup study. J Clin Onco 2006; 24:5687-5694
56. Magné N, Chargari C, Vicenzi L, et al. New trends in the evaluation and treatment of cervix cancer: The role of FDG-PET. Cancer Treat Rev 2008; 34:671-681
57. Grigsby PW, Siegel BA, Dehdashti F. Lymph node staging by PET in patients with carcinoma of the cervix. J Clin Oncol 2001; 19:3745-3749
58. Lee JH, Kim J, Moon HJ, et al. Supraclavicular lymph nodes detected by 18F-FDG PET/CT in cancer patients: Assessment with 18F-FDG PET/CT and sonography. AJR 2012; 198:187-193
59. Yildirim Y, Sehirali S, Avci ME, et al. Integrated PET/CT for the evaluation of para-Aortic nodal metastasis in locally advanced cervical cancer patients with negative conventional CT findings. Gynecol Oncol 2008; 108:154-159
60. Loft A, Berthelsen AK, Roed H, et al. The diagnostic value of PET/CT scanning in patients with cervical cancer: A prospective study. Gynecol Oncol 2007; 106:29-34
61. Wright JD, Dehdashti F, Herzog TJ, et al. Preoperative lymph node staging of early-stage cervical carcinoma by [18F]-fluoro-2-deoxy-D-glucosepositron emission tomography. Cancer 2005; 104:2484-2491
62. Havrilesky LJ, Kulasingam SL, Matchar DB, Myers ER. FDG-PET for management of cervical and ovarian cancer. Gynecol Oncol 2005; 97:183-191
63. Singh AK, Grigsby PW, Dehdashti F, Herzog TJ, Siegel BA. FDG-PET lymph node staging and survival of patients with FIGO stage IIIb cervical carcinoma. Int J Radiat Oncol Biol Phys 2003; 56:489-493
64. Rose PG, Adler LP, Rodriguez M, Faulhaber PF, Abdul-Karim FW, Miraldi F. Positron emission tomography for evaluating para-Aortic nodal metastasis in locally advanced cervical cancer before surgical staging: A surgicopathologic study. J Clin Oncol 1999; 17:41-45
65. Sugawara Y, Eisbruch A, Kosuda S, Recker BE, Kison PV, Wahl RL. Evaluation of FDG PET inpatients with cervical cancer. J Nucl Med 1999; 40:1125-1131
66. Loubeyre P, Navarria I, Undurraga M, et al. Is imaging relevant for treatment choice in early stage cervical uterine cancer? Surg Oncol 2012; 21:e1-e6
67. Bentivegna E, Uzan C, Gouy S, et al. Correlation between [18F]fluorodeoxyglucose positron-emission tomography scan and histology of pelvic nodes in early-stage cervical cancer. Anticancer Res 2010; 30:1029-1032
68. Lagasse LD, Creasman WT, Shingleton HM, Ford JH, Blessing JA. Results and complications of operative staging in cervical cancer: Experience of the Gynecologic Oncology Group. Gynecol Oncol 1980; 9:90-98
69. Wong TZ, Jones EL, Coleman RE. Positron emission tomography with 2-deoxy-2-[(18)F]fluoro- D-glucose for evaluating local and distant disease in patients with cervical cancer. Mol Imaging Biol 2004; 6:55-62
70. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-Aortic radiation for high-risk cervical cancer. N Engl J Med 1999; 340:1137-1143
71. Ansink A, de Barros Lopes A, Naik R, Monaghan JM. Recurrent stage IB cervical carcinoma: Evaluation of the effectiveness of routine follow up surveillance. Br J Obstet Gynaecol 1996; 103:1156-1158
72. Stryker JA, Mortel R. Survival following extended field irradiation in carcinoma of cervix metastatic to para-Aortic lymph nodes. Gynecol Oncol 2000; 79:399-405
73. Belhocine T, Thille A, Fridman V, et al. Contribution of whole-body 18FDG PET imaging in the management of cervical cancer. Gynecol Oncol 2002; 87:90-97
74. Haie-Meder C, Mazeron R, Magne N. Clinical evidence on PET-CT for radiation therapy planning in cervix and endometrial cancers. Radiother Oncol 2010; 96:351-355
75. Narayan K, Hicks RJ, Jobling T, Bernshaw D, McKenzie AF. A comparison of MRI and PET scanning in surgically staged loco-regionally advanced cervical cancer: Potential impact on treatment. Int J Gynecol Cancer 2001; 11:263-271
76. Chao A, Ho K, Wang CC, et al. Positron emission tomography in evaluating the feasibility of curative intent in cervical cancer patients with limited distant lymph node metastases. Gynecol Oncol 2008; 110:172-178
77. Lin LL, Mutic S, Low DA, et al. Adaptive brachytherapy treatment planning for cervical cancer using FDG-PET. Int J Radiat Oncol Biol Phys 2007; 67:91-96
78. Malyapa RS, Mutic S, Low DA, et al. Physiologic FDG-PET three-dimensional brachytherapy treatmentplanning for cervical cancer. Int J Radiat Oncol Biol Phys 2002; 54:1140-1146
79. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: Response and outcome. J Clin Oncol 2004; 22:2167-2171
80. Schwarz JK, Siegel BA, Dehdashti F, Grigsby PW. Association of posttherapy positron emission tomography with tumor response and survival in cervical carcinoma. JAMA 2007; 298:2289-2295
81. Heron CW, Husband JE, Williams MP, Dobbs HJ, Cosgrove DO. The value of CT in the diagnosis of recurrent carcinoma of the cervix. Clin Radiol 1988; 39:496-501
82. Crivellaro C, Signorelli M, Guerra L, et al. 18FFDG PET/CT can predict nodal metastases but not recurrence in early stage uterine cervical cancer. Gynecol Oncol 2012; 127:131-135
83. Yilmaz M, Adli M, Celen Z, Zincirkeser S, Dirier A. FDG PET-CT in cervical cancer: Relationship between primary tumor FDG uptake and metastatic potential. Nucl Med Commun 2010; 31:526-531
84. Kidd EA, Grigsby PW. Intratumoral metabolic heterogeneity of cervical cancer. Clin Cancer Res 2008; 14:5236-5241
85. Kidd EA, Siegel BA, Dehdashti F, et al. Lymph node staging by positron emission tomography in cervical cancer: Relationship to prognosis. J Clin Oncol 2010; 28:2108-2113
86. Yoo J, Choi JY, Moon SH, et al. Prognostic significance of volume-based metabolic parameters in uterine cervical cancer determined using 18Ffluorodeoxyglucose positron emission tomography. Int J Gynecol Cancer 2012; 22:1226-1233
87. Sharma DN, Rath GK, Kumar R, et al. Positron emission tomography scan for predicting clinical outcome of patients with recurrent cervical carcinoma following radiation therapy. J Cancer Res Ther 2012; 8:23-27
88. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007; 26:225-239
89. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996; 56:4509-4515
90. Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone). J Nucl Med 2008; 49:201-205
91. Lewis JS, Laforest R, Dehdashti F, Grigsby PW, Welch MJ, Siegel BA. An imaging comparison of 64Cu-ATSM and 60Cu-ATSM in cancer of the uterine cervix. J Nucl Med 2008; 49:1177-1182